Asher Herzog

Cooley advised the underwriters on Centessa Pharmaceuticals’ $380 million initial public offering of 18,975,000 American depositary shares ADSs, which includes the full exercise of the underwriters’ option to purchase additional shares. Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, Jefferies LLC and Evercore Group LLC, acted as joint book-running managers for the offering. Centessa Pharmaceuticals, whose securities now trade on the Nasdaq Global Select Market under the symbol “CNTA,” is a clinical-stage company employing its asset-centric business model to discover, develop and deliver impactful medicines to patients. Partners Div Gupta, Claire Keast-Butler, Josh Kaufman and Geoffrey Starr led the Cooley team.

Cooley advised the underwriters on Crinetics Pharmaceuticals’ $75 million follow-on offering, with SVB Leerink acting as sole bookrunning manager. Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Partner Daniel Goldberg led the Cooley team.

Cooley advised Kadmon Holdings on its offering of $240 million principal amount of 3.625% convertible senior notes due 2027. Kadmon Holdings, whose securities trade on the Nasdaq Global Select Market  under the symbol KDMN, is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Partners Eric Blancard, Mischi a Marca and Jason Savich led the Cooley team.

Cooley advised Billtrust, a leading provider of cloud-based software and integrated payment processing solutions that simplify and automate B2B commerce, on its agreement to combine with South Mountain Merger Corporation, a publicly traded special purpose acquisition company or SPAC. The combined company will continue as a publicly listed entity and have an implied estimated enterprise value of approximately $1.3 billion at closing. Partners Miguel Vega, Nicole Brookshire and Matt Browne led the Cooley team advising Billtrust.

Cooley advised Orphazyme on its $83.8 million initial public offering. Orphazyme, whose American depositary shares now trade on the Nasdaq Global Select Market under the symbol ORPH and ordinary shares trade on Nasdaq Copenhagen under the symbol ORPHA, is a Danish late-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for the treatment of neurodegenerative orphan diseases. Partners Josh Kaufman and Div Gupta and senior associate Mark Ballantyne led the Cooley team.